Urinary TGF-β1 as a Tumor Marker in Liver Cancer
Author Information
Author(s): JF Tsai, JE Jeng, LY Chuang, ML Yang, MS Ho, WY Chang, MY Hsieh, ZY Lin, JH Tsai
Primary Institution: Kaohsiung Medical College, Taiwan
Hypothesis
Elevated urinary TGF-β1 levels can serve as a tumor marker and predictor of poor survival in patients with cirrhotic hepatocellular carcinoma.
Conclusion
Elevated urinary TGF-β1 levels are associated with poor survival in patients with cirrhotic hepatocellular carcinoma.
Supporting Evidence
- TGF-β1 levels in HCC patients were significantly higher than in cirrhosis alone or healthy controls (P = 0.0001).
- An inverse correlation was found between TGF-β1 and AFP levels (r = -0.292, P = 0.004).
- Median survival in HCC patients with raised TGF-β1 was shorter than those with normal levels (P = 0.018).
- TGF-β1 levels decreased after complete treatment with transcatheter arterial chemoembolization (P = 0.0001).
- Multivariate analysis indicated that TGF-β1 and AFP were significantly correlated with the presence of HCC.
Takeaway
This study found that higher levels of a substance called TGF-β1 in urine can help doctors tell if someone has a serious liver cancer and how well they might do.
Methodology
Urinary TGF-β1 and serum AFP levels were measured in patients with cirrhotic HCC, cirrhosis alone, and healthy controls.
Limitations
The study did not determine plasma TGF-β1 levels and relied on urinary samples.
Participant Demographics
94 patients with cirrhotic HCC, 94 age- and sex-matched patients with cirrhosis alone, and 50 healthy adults.
Statistical Information
P-Value
0.0001
Confidence Interval
95% CI 128-210 days
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website